Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Braeden Lichti is, as of the date of this Schedule 13G, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 33,151 shares of enVVeno Medical Corporation ("Issuer") beneficially owned by Mr. Lichti, out of 655,606 shares of the Issuer's issued and outstanding shares of common stock, par value $0.00001 per share ("Common Stock") on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission ("Commission") on January 20, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Braeden Lichti is, as of the date of this Schedule 13G, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 20,129 shares beneficially owned by Northstrive Fund II LP, out of 655,606 shares of the Issuer's issued and outstanding shares of Common Stock on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 20, 2026.


SCHEDULE 13G



 
Braeden Lichti
 
Signature:/s/ Braeden Lichti
Name/Title:Braeden Lichti
Date:02/10/2026
 
Northstrive Fund II LP
 
Signature:/s/ Braeden Lichti
Name/Title:Braeden Lichti/Manager
Date:02/10/2026